Can Muslims invest in BMY?

BMY passes some but not all shariah screens. Some scholars may permit investing with purification of non-compliant income, while others advise avoiding it. Consult a qualified scholar.

What shariah screening criteria were used for BMY?

BMY was screened using AAOIFI-based criteria: (1) Business activity — must not derive primary income from haram activities, (2) Debt-to-market-cap ratio must be ≤33%, (3) Interest income must be ≤5% of revenue, (4) Cash & interest-bearing securities must be ≤33% of market cap. BMY passed 3 of these 4 screens.

Back to home

Is BMY (Bristol-Myers Squibb Company) Halal or Haram?

Q: Is BMY (Bristol-Myers Squibb Company) stock halal?

Based on our AAOIFI-standard screening, BMY is classified as Doubtful. Bristol-Myers Squibb holds a Doubtful shariah compliance status due to its high debt load, which currently sits at 39.9% of its market capitalization, exceeding the AAOIFI threshold of 33%. While the company's core pharmaceutical business and interest income ratio of 0.62% are fully compliant, the elevated leverage makes it unsuitable for strict halal portfolios at this time.

New York Stock ExchangeHealthcareDrug Manufacturers - General$118.15B2026-04-29

BMY is Doubtful3/4 screens passed

Bristol-Myers Squibb holds a Doubtful shariah compliance status due to its high debt load, which currently sits at 39.9% of its market capitalization, exceeding the AAOIFI threshold of 33%. While the company's core pharmaceutical business and interest income ratio of 0.62% are fully compliant, the elevated leverage makes it unsuitable for strict halal portfolios at this time.

Price Chart (5D)

$56.48+2.23 (+4.10%)

2026-06-092026-06-02

BMY — Last 7 Days

Date	Open	High	Low	Close	Volume	Change
2026-06-09	56.03	56.53	55.26	56.48	11.9M	+0.80%
2026-06-08	57.16	57.42	55.53	55.57	12.3M	-2.78%
2026-06-05	57.03	57.82	56.79	57.27	9.6M	+0.42%
2026-06-04	55.75	56.78	55.55	56.60	12.7M	+1.52%
2026-06-03	54.56	55.09	54.31	54.72	11.5M	+0.29%
2026-06-02	54.78	55.59	54.20	54.46	13.7M	-0.58%
2026-06-01	57.40	57.45	54.71	54.95	20.6M	-4.27%

Discussion

Loading comments...

Shariah Screening Details for BMY

Business Activity

Permissible

Bristol-Myers Squibb passes the business activity screen as its core operations in developing and manufacturing life-saving biopharmaceuticals like Revlimid and Eliquis are entirely permissible under Islamic principles.

Debt / Market Cap

39.90%

Debt: $47.14BThreshold: ≤33%

Interest Income

0.62%

Interest: $300.0MThreshold: ≤5%

Cash & Securities

9.03%

Cash: $10.67BThreshold: ≤33%

About Bristol-Myers Squibb Company (BMY)

For Muslim investors relying on AAOIFI standards, BMY currently holds a Doubtful status. Although its core pharmaceutical operations are perfectly halal, the stock fails the financial screening criteria due to excessive interest-bearing debt, meaning it cannot be confidently added to a shariah-compliant portfolio right now.

The primary concern from an Islamic finance perspective is the company's Debt-to-Market Cap ratio, which stands at 39.9%, notably above the 33% acceptable limit. On a positive note, its interest income is minimal at just 0.62% of revenue, and its cash reserves are well within permissible bounds at 9.0%.

Halal investors should monitor BMY's balance sheet over the coming quarters. If the company aggressively pays down its debt or if its market capitalization increases sufficiently to drop the debt ratio below 33%, it could return to a fully compliant status.

CEO

Christopher S. Boerner

Employees

34,100

IPO Date

1972-06-01

Headquarters

Princeton, NJ, US

Website

www.bms.com

BMY Key Financial Statistics

Revenue

$48.19B

Net Income

$7.05B

EPS (Diluted)

$3.45

Stock Price

57.87

Beta

0.27

52-Week Range

42.52-62.89

Total Debt

$47.14B

Total Equity

$18.47B

Current Ratio

1.26

BMY Financial Health & Profitability

Profit Margins

Gross Margin67.6%

Operating Margin26.3%

Net Margin14.6%

Revenue Growth (YoY)

-0.2%

Prior year: $48.30B

Net Debt

$36.93B

Cash: $10.21B — Debt: $47.14B

R&D Spending

$9.61B

% of Revenue

19.9%

Frequently Asked Questions About BMY

Is BMY (Bristol-Myers Squibb Company) stock halal to invest in?▾

Based on our AAOIFI-standard shariah screening, BMY is classified as Doubtful. It passed 3 of 4 compliance screens. Some scholars may permit investing with income purification, while others advise avoiding it. We recommend consulting a qualified Islamic scholar before investing in BMY.

What does Bristol-Myers Squibb Company do?▾

Bristol-Myers Squibb Company (BMY) is a major global biopharmaceutical firm dedicated to discovering and manufacturing treatments for severe diseases. The company's portfolio includes blockbuster drugs like the blood thinner Eliquis, the cancer immunotherapy Opdivo, and Revlimid for multiple myeloma. For Muslim investors relying on AAOIFI standards, BMY currently holds a Doubtful status. Although its core pharmaceutical operations are perfectly halal, the stock fails the financial screening criteria due to excessive interest-bearing debt, meaning it cannot be confidently added to a shariah-compliant portfolio right now. The primary concern from an Islamic finance perspective is the company's Debt-to-Market Cap ratio, which stands at 39.9%, notably above the 33% acceptable limit. On a positive note, its interest income is minimal at just 0.62% of revenue, and its cash reserves are well within permissible bounds at 9.0%. Halal investors should monitor BMY's balance sheet over the coming quarters. If the company aggressively pays down its debt or if its market capitalization increases sufficiently to drop the debt ratio below 33%, it could return to a fully compliant status. Bristol-Myers Squibb Company operates in the Healthcare sector under the Drug Manufacturers - General industry and is headquartered in Princeton, NJ, US. The company is led by CEO Christopher S. Boerner and employs approximately 34,100 people.

What screening criteria were used for BMY?▾

BMY was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. BMY passed 3 of these 4 screens.

When was BMY last screened?▾

BMY was last screened on 2026-04-29. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.

Disclaimer

This shariah compliance assessment for BMY (Bristol-Myers Squibb Company) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.

Other Screened Stocks in Healthcare

AHealthcare

Halal

Agilent Technologies, Inc.

AbbVie Inc.

Abbott Laboratories

Align Technology, Inc.